Opinion|Videos|August 19, 2024
Patient’s Goals and Atopic Dermatitis Treatment Selection
Lindsay S. Ackerman, MD, FAAD, and Jonathan Silverberg, MD, PhD, MPH, discuss how patient goals inform treatment decisions for patients with atopic dermatitis.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- How important are patient goals in atopic dermatitis treatment selection?
- How critical is it to set clear expectations of treatment in atopic dermatitis?
Advertisement
Related to this article
KT-621, an oral STAT6 degrader, cut mean EASI by 62.6% after 4 weeks with no treatment-related adverse events in a phase 1b atopic dermatitis study.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
Lindsay Ackerman, MD, and Chris Bunick, MD, PhD, examine how ORAL Surveillance shaped JAK warnings and what long-term atopic dermatitis data show.
Advertisement
Advertisement
Trending on HCPLive
1
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
2
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
3
ELSPIRE: Elafibranor Achieves ALP Normalization in 85% With PBC
4
Oral STAT6 Degrader KT-621 Reduces EASI by 62.6% in Atopic Dermatitis
5